Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of NIO752 in progressive supranuclear palsy
CTR20261549Phase 3Active
- Sponsor
- Novartis
- Start
- Jul 2026
- Modality
- Vaccine mRNA → mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of NIO752 in progressive supranuclear palsy (PSP), sponsored by Novartis. Started Jul 2026; status: active.
02
Drugs
NIO752
03
Conditions
progressive supranuclear palsy (PSP)
Beyond the preview
Go deeper on CTR20261549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261549.